Table 3 Outcomes in selenium and control groups
From: Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial
Outcomes | Selenium supplementation group | Controls | p value |
|---|---|---|---|
Primary outcome | |||
Composite endpoints | 36 (78.3%) | 43 (79.6%) | 0.867 |
All-cause deaths | 3 (6.5%) | 9 (16.7%) | 0.137 |
NYHA II to IV | 18 (39.1%) | 37 (68.5%) | 0.006* |
LVEF< 55.0% | 33 (71.7%) | 38 (70.4%) | 0.944 |
Secondary outcome | |||
Rehospitalisatons | 4 (8.7%) | 8 (14.8%) | 0.533 |